RDUS - Total Utang marang Modal Radius Pharmaceuticals

Logo perusahaan publik Radius Recycling, Inc. (RDUS)

The price chart for Radius Recycling, Inc. (RDUS) demonstrates the 1.13 level, while the business relies on outsourced drug synthesis via US CMO facilities. Simultaneously, Radius Recycling, Inc. (RDUS) is developing partnerships with municipal services and plants for metal recycling. The current trajectory focuses on implementing AI-driven sorting and equipment modernization, replacing the search for new pharmaceutical formulas with the applied upgrading of its technical base.

RDUS: Total Utang marang Modal Radius Recycling 04.07.2022 - 26.07.2025

Rincian analitis perusahaan Radius Recycling, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Radius Recycling|RDUS - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Radius Recycling|RDUS - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Radius Recycling|RDUS - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku radiuspharm.com|RDUS - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Radius Recycling, Inc.|RDUS - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Radius Recycling, Inc.|RDUS - Gunggung utang perusahaan|Utang marang nilai buku Radius Recycling|RDUS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Radius Recycling|Rasio cepet radiuspharm.com
- informasi bathi lan kelipatan valuasi:
RDUS - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Radius Recycling
Barang utama Radius Pharmaceuticals

To minimize fundamental risks, investors select assets with controlled leverage, where the ratio of total liabilities to equity determines the business's dependence on borrowed funds. The current value of 1.13 reflects the financial stability of Radius Recycling, Inc. (RDUS) during a period of liquidity austerity and a pivot away from mergers, making the business's leverage ratio a key indicator of the company's survivability under cyclical pressure.

Analisis pesaing Radius Recycling, Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|SGMT (Sagimet) - Total Utang marang Modal|Total Utang marang Modal BioAge Labs, Inc|Total Utang marang Modal BMEA|Utang marang Ekuitas QNCX (quincetx.com)|Utang marang Ekuitas Fractyl Health GUTS|vTv Therapeutics, Inc. (VTVT) - Utang marang Modal|ATPC - Utang marang Ekuitas|PLUR: Utang marang Ekuitas|SYBX: Total Utang marang Modal|LPCN - Koefisien Total Utang marang Modal|Utang marang Ekuitas Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Galecto Corp (GLTO)|Rasio Total Utang marang Ekuitas Carmell Therapeutics CTCX|Utang marang Ekuitas Lumos Pharma, Inc. LUMO|Rasio Kabeh Utang marang Dana Pribadi ONVO